FindMyKOL
Clinical trialNCT01093885CompletedInterventional

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

NCT01093885 is an interventional trial sponsored by University of Pennsylvania. As of 21 Nov 2026, it is completed. It studies Ambrisentan in Scleroderma and Systemic Sclerosis. The registry lists an enrollment of 15 participants at 1 site in 1 country. The registry lists a start date of 28 Feb 2010 and a primary completion date of 31 Jul 2016.

SponsorUniversity of Pennsylvania →Enrollment15SclerodermaSystemic Sclerosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01093885
FieldValue
Registry IDNCT01093885
StatusCompleted
Study typeInterventional trial
Lead sponsorUniversity of Pennsylvania
Enrollment15
Registered sites1
Countries1
ConditionsScleroderma and Systemic Sclerosis
DrugsAmbrisentan
Start28 Feb 2010
Primary completion31 Jul 2016
Study completion31 Jul 2016
Last update posted29 Nov 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Systemic sclerosis is a chronic autoimmune connective tissue disorder with no universally accepted disease modifying regimen. Recruiting patients for systemic sclerosis treatment studies is difficult due to the limited availability of such patients and furthermore the use of a placebo arm is often deemed unethical due to the poor survival of diffuse systemic sclerosis patients. Long-term controlled trials examining functional outcomes and survival from novel therapeutic agents for systemic sclerosis are often difficult to undertake because of costs, rarity of the disease and ethical issues with the use of a true placebo. Open label single center studies while inferior to multicenter placebo controlled studies, have helped establish the benefits of certain pharmaceutical agents in systemic sclerosis, and while not universally accepted as disease modifying agents, have been used with some success to treat systemic sclerosis. The hypothesis on which we are basing this study is that an endothelin receptor antagonist and disease modifying agent with antifibrotic properties will have additive influence on fibrosis, inhibit cellular and humoral hyperactivity and interfere with smooth muscle proliferation in the vessel wall. The combination of these two agents will also be the first regimen to address the heterogeneity of scleroderma manifestations including ILD, pulmonary arterial hypertension and skin manifestations

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • University of Pennsylvania Health System

    Philadelphia

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01093885

Each answer restates registry values shown on this page.

What is NCT01093885?

NCT01093885 is an interventional trial sponsored by University of Pennsylvania. It studies Ambrisentan in Scleroderma and Systemic Sclerosis.

Who leads NCT01093885?

The registry names Chris Derk, MD, MSc (principal investigator, University of Pennsylvania) as the overall official.

Where does NCT01093885 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01093885 study?

The registered drug and biological interventions are Ambrisentan.

When did NCT01093885 end?

The registry lists a primary completion date of 31 Jul 2016 and a study completion date of 31 Jul 2016. The sponsor last updated the record on 29 Nov 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.